Dear Physician/Scientist,
You are cordially invited to participate in the research conference " The JC Bystryn Pemphigus & Pemphigoid Meeting: from the bench to the bedside" to be held on November 5 and 6, 2010 in Bethesda, Maryland, USA. This will be the third international meeting co-sponsored by the International Pemphigus and Pemphigoid Foundation (IPPF) and National Institute of Arthritis and Musculoskeletal and Skin Disease (NIAMS), NIH.
The meeting will bring together physicians and scientists interested in these diseases to meet face-to-face and facilitate interactions. The goal is to identify areas of research opportunity that will promote our understanding of the causes and provide experimental and clinical justification for novel treatments of pemphigus and pemphigoid.
This meeting is expected to have a dramatic impact on the development of coordinated efforts of the international group that drive the field of immunobullous dermatoses. We hope to generate consensus on the terminology and criteria that should be used to describe in a uniform manner severity of the diseases and their response to therapy.
We are looking forward to see you in Bethesda.
Yours sincerely,
S. A. Grando, L. A. Diaz, and V. Werth
Scientific Committee Members
This will be the third research conference sponsored by the International Pemphigus and Pemphigoid Foundation (IPPF; formerly International Pemphigus Foundation) and supported by NIAMS.
Previous IPPF conferences on pemphigus were held on the NIH campus in 2001 ("Pemphigus as a Model of Organ-specific Autoimmune Disease") 2005 ("Pemphigus 2005 - Progress and Future Directions"). These conferences were very successful and attracted approximately 150 participants each. The third conference will represent a strong collaborative effort between scientists, clinical researchers, and IPPF. It will facilitate continued work to advance the science and translational aspects of the studies on autoimmune blistering diseases. The critical involvement of the IPPF assures community and patient awareness about this important meeting. Given the many advances in both the scientific understanding and therapeutic immunologic approaches, this is a timely opportunity for the proposed meeting.
This conference will:
- highlight recent advances in defining the pathogenesis of pemphigus and pemphigoid, so as to identify areas of research opportunity that will most effectively promote our understanding of the causes of these severe disease, and improve treatment outcomes;
- discuss the feasibility of setting up cooperative multinational endeavors, so as to: i) define agreed upon algorithm to treat patients with pemphigus or pemphigoid; and ii) conduct multi-institutional randomized trials; and
- respond to patient’s requests and needs for better information and for more rapid progress in the treatment of these orphan diseases, in order to focus attention of the participants on the ultimate need that must be met.
The theme of this meeting touches on a unique facet of public health interest, connecting the basic science efforts (the "bench") to their clinical applications (the "bedside"). Both the basic researchers and the clinicians with interest in immunobullous diseases will jointly discuss recently published and yet unpublished research data and treatment outcomes. The opportunity created within such a focused interest group in an informal environment will contribute to the emerging of novel ideas to resolve existing problems with treatment, and establishing fruitful collaborations.
PRELIMINARY PROGRAM
"Pemphigus & Pemphigoid: from the bench to the bedside"
November 5 & 6, 2010
DAY 1
Morning Sessions 8:00-12:00
INTRODUCTION 8:00-8:15
- Welcome from the Organizers (Sergei Grando)
- NIH speaker (Stephen I. Katz)
- IPPF speaker (David Sirois)
- Tribute to Jean-Claude Bystryn (1938-2010): a legendary man and history parallels (Karl Holubar)
Session 1: AUTOANTIBODIES IN THE PATHOGENESIS OF PEMPHIGUS AND PEMPHIGOID Chair: Luis A. Diaz; Co-chair: Stephen I. Katz (8:15 to 12:00)
The bench (Role of autoantibodies in pathogenesis) (8:15 -9:45)
- Etiological factors involved on pathogenic autoantibody responses in man - Stephen Clarke 30 min
- Diversity of the autoantibody response in pemphigus (IgM, IgE, IgG subclasses) - Luis Diaz 15 min
- Pathogenic scFv & V genes from pemphigus vulgaris autoantibodies - John Stanley 15 min
- V gene repertoire in pemphigus foliaceus autoantibodies - Ye Qian 15 min
- Review of autoantibodies against all known non-desmoglein antigens in pemphigus - Aimee Payne 15 min
Coffee 9:45 -10:00
The bedside (Update on removing pathogenic antibodies) (10:00 - 12:00)
- Review of IVIG in pemphigus and pemphigoid & mechanism of action - Annette Czernik 15 min
- Review of Rituxan - Grant Anhalt 15 min
- Review of Immunoadsorption/plasmapheresis - Rudiger Eming 15 min
Selected abstracts 10 min each
Group Discussion 40 min
Lunch: Update on International Consensus on Definitions in Pemphigus and Pemphigoid
Moderators: Victoria Werth and Dedee Murrell (12:00-1:00)
Afternoon Sessions 1:00-5:05
Session 2: MOLECULAR MECHANISMS OF BLISTERING IN PEMPHIGUS AND PEMPHIGOID
Chair: Sergei A. Grando; Co-chair: Detlef Zillikens
Part I. ACANTHOLYSIS IN PEMPHIGUS (1:00-2:55)
The bench (Update on molecular mechanisms of intraepidermal detachment)
- Desmoglein signaling: active vs. passive - Jens Waschke 15 min
- Review of Fas system involvement - Carlo Pincelli 15 min
- Apoptolysis - Sergei Grando 15 min
The bedside (Blocking signaling pathways as therapy)
- Animal studies of inhibitors of signaling pathways - Augustin España 15 min
- Human studies of blocking signaling pathways - David Rubenstein 15 min
Selected abstracts 10 min each
Group Discussion 20 min
Coffee 2:55 - 3:10
Part II. EPIDERMAL DETACHMENT IN PEMPHIGOID (3:10-5:05)
The bench (Update on molecular mechanisms of subepidermal detachment)
- Molecular mechanisms of dermal-epidermal separation in bullous pemphigoid vs. mucous membrane pemphigoid - Kim Yancey 15 min
- Blocking autoantibody induced injury of the dermal-epidermal junction - Zhi Liu 15 min
- Role of IgE in the pathogenesis of bullous pemphigoid - John Zone 15 min
The bedside (Blocking signaling pathways as therapy)
- Biologicals in pemphigoid - Detlef Zillikens 15 min
- Anti-IgE therapy of bullous pemphigoid - Janet Fairley 15 min
Selected abstracts 10 min each
Group Discussion 20 min
POSTER VIEWING with COCKTAIL RECEPTION (self pay) 5:30-8:00
DAY 2
Morning session 8:30-noon
Session 3: T CELLS AND CYTOKINES IN THE PATHOGENESIS OF PEMPHIGUS AND PEMPHIGOID
Chair: Victoria Werth, Co-chair: Michael Hertl (8:30-11:55)
The bench (Regulation of antibody production and inflammation) (8:30-10:00)
- Mechanisms of autoimmunity: cellular and molecular events - Paolo Casali 30 min
- Regulation of pathogenic autoantibody production in pemphigus and pemphigoid - Masayuki Amagai 15 min
- T cell control in pemphigus and pemphigoid - Michael Hertl 15 min
- Cytokines in pemphigus and pemphigoid: Epiphenomena or contribution to pathogenesis? - Enno Schmidt 15 min
- Immunoprofiling to unravel disease complexity in pemphigus - Animesh Sinha 15 min
Coffee10:00-10:15
The bedside (Anti-cytokine therapy for pemphigus and pemphigoid) (10:15-11:55)
- TNF inhibitors in pemphigus - Russell Hall 15 min
- Rituximab control of T cells - Mary Tomayko 15 min
Selected abstracts 10 min each
Group Discussion 30 min
Lunch: Overcoming Obstacles To Organizing Multicenter Trials For Blistering Diseases
Moderators: Victoria Werth and Russell Hall (12:00-1:00)
Afternoon session 1:00-3:00 PM
Session 4: TOWARDS AN ALGORITHM FOR THE TREATMENT OF PEMPHIGUS (Group discussion by clinicians interested in developing guidelines for the diagnosis, evaluation and treatment of pemphigus)
Chair: Grant Analth, Co-chair: Masayuki Amagai
Review of the US experience - Grant Anhalt 15 min
Review of the European experience - TBD 15 min
Review of the Asian experience Masayuki Amagai 15 min
Review of the Middle Eastern/Indian experience - Cheyda Chams-Davatchi 15 min
Group Discussion 45 min
CLOSING REMARKS FROM THE ORGANIZERS
(Luis Diaz, Victoria Werth) 2:45-3:00
The speakers are all recognized authorities in their field and many have international reputations. They include individuals from the US, Europe, Asia, and the Middle East.
TRIBUTE TO DR. JC BYSTRYN
Karl Holubar - Austria
AUTOANTIBODIES IN THE PATHOGENESIS OF PEMPHIGUS AND PEMPHIGOID
Stephen Clarke - USA
Annete Czernik - USA
Luis Diaz - USA
Rudiger Eming - Germany
Aimee Payne - USA
Ye Qian - USA
John Stanley - USA
MOLECULAR MECHANISMS OF ACANTHOLYSIS IN PEMPHIGUS
Augustin España - Spain
Sergei Grando - USA
Marcel Jonkman - the Netherlands
Carlo Pincelli - Italy
David Rubenstein - USA
Jens Waschke - Germany
MOLECULAR MECHANISMS OF EPIDERMAL DETACHMENT IN PEMPHIGOID
Janett Fairley - USA
Zhi Liu - USA
John Zone - USA
Kim Yancey - USA
Detlef Zillikens - Germany
T CELLS AND CYTOKINES IN THE PATHOGENESIS OF PEMPHIGUS AND PEMPHIGOID
Masayuki Amagai - Japan
Paolo Casali - USA
Russell Hall - USA
Michael Hertl - Germany
Enno Schmidt - Germany
Animesh Sinha - USA
Mary Tomayko - USA
DEVELOPMENT OF ALGORITHM FOR THE TREATMENT OF PEMPHIGUS
Masayuki Amagai - Japan
Grant Anhalt - USA
Cheyda Chams-Davatchi - Iran
Dedee Murrell - Australia
Victoria Werth - USA
NOTE: HOTEL REGISTRATION is being done SEPARATELY and can be done by visiting https://resweb.passkey.com/go/IPPF or calling 888-421-1442 and using the registration code IPPF.
The IPPF is offering registration to the 3rd International Science Conference, "Pemphigus & Pemphigoid: from the bench to the bedside" through Eventbrite.com with payment through PayPal or sending a check with a completed registration form.
As an incentive to medical students and residents, the registration fee has been waived. Please order your tickets below, click Enter Discount Code and use the code student or resident and press the Apply Discount button in order for the discount to be applied. Select your ticket registration quantity, then click on the Register button. Speakers please use code speaker.
PayPal processes payments for the IPPF. You do not have to have a PayPal account to proceed, just click on the Continue link shown below:
